RSNA Quantitative Imaging Committee (QUIC) FAQs Summary:

In 2007, RSNA organized the Quantitative Imaging Biomarkers Alliance (QIBA) to unite researchers, healthcare professionals and industry to advance quantitative imaging and the use of imaging biomarkers in clinical trials and clinical practice. QIBA’s mission has been to improve the value and practicality of quantitative imaging biomarkers by reducing variability across devices, sites, patients, and time. Periodic reviews have been scheduled to evaluate the progress and long-term vision for QIBA. After in-depth study of the latest review, the RSNA Board of Directors approved modifying the current infrastructure of QIBA.

The RSNA Board established a quantitative imaging committee to better achieve QIBA’s mission and further the use of quantitative imaging in clinical trials and the clinic. The Board is grateful to the volunteers and staff who contributed to the formation of QIBA and who continue to enhance the value and practicality of quantitative imaging biomarkers to improve patient care.

The committee structure broadens the charge of RSNA’s quantitative imaging efforts beyond biomarker Profiles. The committee will include RSNA members (radiologists) and thought leaders from relevant stakeholder groups, including industry, government, and partner societies and organizations. The committee charge will include:

- Creation of a mechanism whereby imaging Profiles can be submitted by outside entities for RSNA endorsement.
- Oversight of one to three biomarker committees selected for their clinical trial/clinical care applicability.
- Education of the radiology community about the importance of quantitative imaging, availability of QI Profiles, and tools to encourage standardization.
- Collaboration with imaging organizations and vendors to promote QI and standardization.
- Outreach to stakeholders to proactively address end-user needs and advance the adoption of Profiles, including stakeholders from academia, industry, regulatory agencies, patient advocacy groups, and medical imaging societies; and
- Advocacy to promote the association of QI for AI among RSNA members.

**QUESTIONS & ANSWERS:**

**QUIC Overview**

1. What are the new goals and broader objectives of the Quantitative Imaging Committee (QUIC)?
   - Implementation of quantitative imaging in clinical trials and clinical practice, looking beyond Profile development and publication.
     1. Radiologist education
     2. Government and industry outreach and advocacy
     3. Medical society collaboration
   - Building a library of published QIBA Profiles.
     1. Focused, timely QIBA Profile authoring with direct stakeholder/end-user participation
     2. Endorsement of QIBA Profiles from external authoring groups

2. What is RSNA’s vision of success?
   - QIBA standards and quantitative imaging are used regularly in the clinic or clinical trials.
   - Specific, measurable goals will be set by the committee for review every 3 years.
3. Who will be involved in the QUIC?
   - RSNA is in the process of identifying and soliciting volunteers and verifying appropriate stakeholders.
   - Please volunteer! Declaration of interest and recommendations should be sent to qiba@rsna.org.

4. Will the QUIC be an open or closed committee?
   - The QUIC will be a formal RSNA committee with appointed members.
   - The QUIC will collaborate/partner with other professional organizations and individuals, e.g., AAPM, medical societies, and clinical trialists.

5. Does this change reflect a decision to pursue alternate standardization approaches?
   - No, the committee will build on the many years of rigorous contributions made by QIBA volunteers.
   - The committee will promote the adoption of quantitative imaging more broadly in the clinic and clinical trials (beyond QIB work).

6. How does the QUIC plan to improve Profile deployment and implementation/adoption?
   - Convene a stakeholder forum to discuss and assess the primary QI needs and barriers to adoption of radiologists and the imaging community.
   - Work closely with industry to develop consistent standards across scanners and vendors.
   - Focus on 1-3 biomarkers as a pilot implementation path.
   - Raise the recognition of QI value among the radiology community and beyond.
   - Collaborate with accreditation providers and medical societies to provide the opportunity for greater Profile implementation.

QIBA Transition To QUIC

7. What is the timing of the transition?
   - RSNA administrative support for Biomarker Committees (BCs) will continue through December 22, 2023, with the goal of advancing each Profile to the next stage.
   - BCs are encouraged to continue working independently of RSNA administrative support after December 22, 2023, when Profiles may be submitted to the QUIC for endorsement and inclusion in the QIBA Profile Library.
   - The QUIC will assume QIBA governance on December 22, 2023.

8. What will happen to standing and new collaborations? Will international collaborations with QIBA/EIBALL, EARL, J-QIBA, and NIF continue?
   - Yes, collaborations will be critical to the charge of QUIC.
   - Partners will be included as stakeholders in the new committee or relevant advisory groups. This includes societies, industry groups, government groups, and other international QI efforts.

9. Will funding support change after the transition?
   - No, RSNA will continue to support quantitative imaging initiatives through the broader scope of the new committee.
10. Will the QIBA brand be maintained?
   - Yes, published Profiles will be identified as QIBA branded documents, be published in the Profile Library and receive DOIs.
   - Additional Profiles may be added to the QIBA Profile Library after endorsement by the committee.

11. How will QUIC select biomarker authoring groups? Can current BCs "apply" to be one of the authoring groups?
   - Biomarker authoring groups will be launched once the selection criteria and application process are determined by the QUIC.
   - There will be an application process similar to that for new biomarker consideration that will include identifying the biomarker use case(s) and development timeline.
   - Recommendations will be provided in accordance with the strength of evidence of publications corresponding to each imaging biomarker combined with the expert opinion of the members of the authoring group.

12. What is the process for submitting Profiles to the committee for publishing on the QIBA Profile Library?
   - The QUIC endorsement subcommittee will establish a submission and review process.
   - The submission process will consider Profiles at Stage 2 (Consensus) or later, with target audience and clinical use case(s) clearly identified.

13. Will Profiles be updated to accommodate technology or clinical practice changes?
   - Yes, dedicated authoring groups are welcome to make updates as needed, e.g., partnering societies could oversee periodic Profile maintenance of their own documents.
   - Profiles will be reviewed and assessed for continued relevance to clinical use by the QUIC on a regular basis.

**Other Questions**

14. Will the Wiki BC page content be available and open for updating?
   - Yes, the Wiki will continue to be accessible to the public and BC leaders will have editing privileges.
   - BC leaders will be encouraged to update their committee pages, post material/call summaries, etc. to best support their continued activities.
   - Wiki instructions are available from staff.

15. Will the 2023 QIBA Task Force Report be made available?
   - The Task Force Report is a confidential document.
   - The report evaluated QIBA progress against the recommendations from the 2011 Task Force.
   - The 2023 Task Force Report informed discussions by the RSNA Science Council and RSNA Board but did not include specific recommendations for infrastructure changes.
16. How will the transition impact conformance initiatives, such as the EARL/QIBA conformance initiative?
   - Conformance verification by volunteers will be considered when a sustainable and scalable model is available.
   - Conformance verification by 3rd party vendors to published Profiles will be continued on a case-by-case basis.

17. How long will the Metrology/Process Committee support last for QIBA/QUIC?
   - Statistical support will be considered on an as needed basis after December 22, 2023.
   - Processes will be determined by the QUIC after December 22, 2023.

18. Will the videos created that describe QIBA and our efforts remain accessible on the Wiki?
   - Yes, videos will remain publicly accessible on the RSNA YouTube channel and linked from the Wiki.

19. Will the Academy CECI² Fellowship continue after the transition?
   - CECI² Fellowships with the Academy remain an important collaboration and are planned to continue.
   - RSNA and Academy leadership are in discussions regarding possible new goals and opportunities for 2024.

20. How should QIBA Profiles be cited?
   - QIBA Profiles are published documents with DOIs. Profile authors can reference QIBA work similarly to their role as authors for other published documents.

21. What will happen to the QIDW and the data and software uploaded to the system?
   - The QIDW will no longer be maintained after the transition.
   - Data submitters will be requested to identify alternate repositories if needed.

22. As QIBA Profiles are explored for use in clinical trials, clinical practice, etc., how will inquiries be managed? To whom shall they be directed?
   - All inquiries should be directed to the QUIC by emailing qiba@rsna.org.